Jupiter Neurosciences licenses exclusive US rights to PharmAla’s ALA-002 in deal valued up to USD 100 million

Reuters2026/07/21 11:13

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jupiter Neurosciences signed a definitive license with PharmAla for perpetual exclusive U.S. rights to ALA-002, valued up to USD 100 million.
USD 3.3 million upfront payment includes USD 1.5 million cash, USD 1.8 million in common stock subject to a 120-day lock-up.
Milestones include USD 3.3 million at Phase 3 first patient in, USD 20 million on U.S. NDA approval, sales-based payments up to USD 73.3 million.
Royalty set at 3% of net sales, starting after the third commercial milestone.
ALA-002 is an FDA NCE-designated, patented non-racemic MDMA candidate; PharmAla will supply GMP drug product under terms to be negotiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210713PRIMZONEFULLFEED9765373) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jupiter Neurosciences licenses exclusive US rights to PharmAla’s ALA-002 in deal valued up to USD 100 million

You may also like

Crypto prices